Form 4: Arcturus Therapeutics Director Acquires Stock Options
Insider Transaction
Arcturus Therapeutics Holdings Inc. Director Jing L. Marantz acquired 15,000 stock options as part of an annual grant.
Summary
- Jing L. Marantz, a Director at Arcturus Therapeutics Holdings Inc., was granted 15,000 stock options on June 5, 2026.
- These options have an exercise price of $7.30 and an expiration date of June 5, 2036.
- The shares underlying the options vest monthly over a one-year period from the grant date.
- This grant represents the 2026 annual award to Marantz for their role on the Board of Directors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard compensation event for a director rather than significant financial results or strategic shifts.
Positives
- Director compensation through stock options aligns management interests with shareholders.
- The grant of options indicates continued investment in leadership and board engagement.
Risks
- The value of the stock options is subject to the future performance of Arcturus Therapeutics' stock price.
- Vesting over one year means the full benefit of the options is not realized immediately.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a transaction related to director compensation.
Industry Context
StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and align executive interests with shareholder value. This type of grant is standard for board members in companies like Arcturus Therapeutics.
Stakeholder Impact
- Shareholders: The grant of options aligns director incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
- Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board.
Next Steps
- Monthly vesting of the granted stock options over the next year.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Date of earliest transaction (grant date of stock options) |
| 06/05/2036 | Expiration date of the granted stock options |
| 06/15/2026 | Date of signature on the filing |
Keywords
Arcturus Therapeutics, ARCT, Form 4, Stock Options, Director Grant, Insider Trading, SEC Filing, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.